Safety profile of cerebrolysin: Clinical experience from dementia and stroke trials

Drugs of Today

Volumn 48, Issue SUPPL. A, 2012, Pages 63-69

  Thome, J ^a   Doppler, E ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b EVER Neuro Pharma GmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CEREBROLYSIN; DONEPEZIL; MONOAMINE OXIDASE INHIBITOR; RECOMBINANT PLASMINOGEN ACTIVATOR; RIVASTIGMINE;

AGITATION; ALLERGIC REACTION; ALZHEIMER DISEASE; ANOREXIA; ANOREXIA NERVOSA; ANXIETY DISORDER; BLEEDING; BRAIN ISCHEMIA; CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG SAFETY; DRUG TOLERANCE; DYSPEPSIA; DYSTHYMIA; FEVER; HEADACHE; HOSPITALIZATION; HUMAN; HYPERSENSITIVITY; HYPERTENSION; INCIDENCE; INSOMNIA; MULTIINFARCT DEMENTIA; MUSCLE SPASM; NAUSEA; OPEN STUDY; POSTMARKETING SURVEILLANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STROKE PATIENT; URINARY TRACT INFECTION; VERTIGO; VOMITING;

AMINO ACIDS; DEMENTIA; HUMANS; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 84860877282     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48(Suppl.A).1739724     Document Type: Review

References (29)

1. Whitehouse, P.J., Sciulli, C.G., Mason, R.M. Dementia drug development: use of information systems to harmonize global drug development. Psychopharmacol Bull 1997, 33(1): 129-33. (Pubitemid 27184207)
2. Alvarez, X.A., Cacabelos, R., Sampedro, C. et al. Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil. Curr Alzheimer Res 2011, 8(5): 583-91.
3. Alvarez, X.A., Cacabelos, R., Laredo, M. et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 2006, 13(1): 43-54.
4. Bae, C.Y., Cho, C.Y., Cho, K. et al. A double-blind, placebocontrolled, multicenter study of Cerebrolysin for Alzheimer's disease. J Am Geriatr Soc 2000, 48(12): 1566-71.
5. Gavrilova, S.I., Kolykhalov, I.V., Korovaitseva, G.I., Zharikov, G.A., Kalyn, Y.B., Selezneva, N.D. [ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease]. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova 2005, 105(4): 27-34. (Pubitemid 44077221)
6. Guekht, A.B., Moessler, H., Novak, P.H., Gusev, E.I. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis 2011, 20(4): 310-8.
7. Muresanu, D.F., Rainer, M., Moessler, H. Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin. J Neural Transm Suppl 2002(62): 277-85. (Pubitemid 37046671)
8. Panisset, M., Gauthier, S., Moessler, H., Windisch, M. Cerebrolysin in Alzheimer's disease: a randomized, doubleblind, placebo-controlled trial with a neurotrophic agent. J Neural Transm 2002, 109(7-8): 1089-104. (Pubitemid 34762347)
9. Ruether, E., Husmann, R., Kinzler, E. et al. A 28-week, double- blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. Int Clin Psychopharmacol 2001, 16(5): 253-63. (Pubitemid 32822444)
10. Ruther, E., Ritter, R., Apecechea, M., Freytag, S., Windisch, M. Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 1994, 27(1): 32-40. (Pubitemid 24078987)
11. Xiao, S., Yan, H., Peifen, Y., Cerebrolysin Study Group The efficacy of Cerebrolysin in patients with vascular dementia: results of Chinese multicenter, randomized, double-blind, placebo-controlled trial. Hong Kong J Psychiatry 1999, 9(2): 13-9. (Pubitemid 30123557)
12. Xiao, S.F., Yan, H.Q., Yao, P.F., Cerebrolysin Study Group. Efficacy of FPF 1070 (cerebrolysin) in patients with Alzheimer's disease - A multicentre, randomised, doubleblind, placebo-controlled trial. Clin Drug Invest 2000, 19(1): 43-53.
13. Rainer, M., Brunnbauer, M., Dunky, A. et al. Therapeutic results with Cerebrolysin in the treatment of dementia. Wien Med Wochenschr 1997, 147(18): 426-31. (Pubitemid 27501970)
14. Allegri, R.F., Guekht, A. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia. Drugs Today 2012, 48(Suppl. A): 25-41.
15. Bornstein, N., Poon, W.S. Accelerated recovery from acute brain injuries: Clinical efficacy of neurotrophic treatment in stroke and traumatic brain injuries. Drugs Today 2012, 48(Suppl. A): 43-61.
16. World Development Report. Investing in Health. Oxford University Press: Oxford 1993.
17. Adams, H.P., Jr., Bendixen, B.H., Kappelle, L.J., Biller, J., Love, B.B., Gordon, D.L., Marsh, E.E., 3rd Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24(1): 35-41. (Pubitemid 23014379)
18. Rosamond, W., Flegal, K., Furie, K. et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117(4): e25-146.
19. Heiss, W.D., Brainin, M., Bornstein, N.M., Tuomilehto, J., Hong, Z., for the Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: Results of a double-blind, placebo-controlled, randomized trial. Stroke 2012, 43(3): 630-6.
20. Hong, Z., Moessler, H., Bornstein, N., Brainin, M., Heiss, W.D. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of Cerebrolysin in patients with acute ischaemic stroke in Asia-CASTA. Int J Stroke 2009, 4(5): 406-12.
21. Ladurner, G., Kalvach, P., Moessler, H. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. J Neural Transm 2005, 112(3): 415-28. (Pubitemid 40868052)
22. Lang, W. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with Alteplase (rt-PA) and Cerebrolysin in acute ischemic stroke. Ebewe/EVER Neuro Pharma data on file, 2009.
23. Bajenaru, O., Tiu, C., Moessler, H., Antochi, F., Muresanu, D., Popescu, B.O., Novak, P. Efficacy and safety of Cerebrolysin in patients with hemorrhagic stroke. J Med Life 2010, 3(2): 137-43.
24. Herrschaft, H. Wirksamkeit von Cerebrolysin bei akutem ischämischem Hirninfarkt. Clinical study report Interner Studienbericht EBEWE/EVER Neuro Pharma 1998.
25. Shamalov, N.A., Stakhovskaia, L.V., Burenchev, D.V. et al. [The effect of cerebrolysin in dosage 50 ml on the volume of lesion in ischemic stroke.] Zh Nevrol Psikhiatr Im S S Korsakova 2010, 110(12, Pt. 2): 34-7.
26. Haffner, Z., Gmeinbauer, R., Moessler, H. A randomized, double-blind, placebo-controlled trial with cerebrolysin in acute ischemic stroke. Cerebrovasc Dis [10th Eur Stroke Conf (May 16-19, Lisbon) 2001] 2001, 11(Suppl. 4): 76.
27. Haffner, Z., Javor, L., Windisch, M., Gmeinbauer, R. Cerebrolysin in acute ischemic stroke. 31st Int Danube Symp Neurological Sci Continuing Ed (Aug 25-29, Szeged, Hungary) 1999.
28. Skvortsova, V.I., Stakhovskaia, L.V., Gubskii, L.V., Shamalov, N.A., Tikhonova, I.V., Smychkov, A.S. [A randomized, doubleblind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova 2004(Suppl. 11): 51-5.
29. Maksimova, M., Briukhov, V.V., Timerbaeva, S.L., Kistenev, B.A., Rebrova, O., Suslina, Z.A. [Effectiveness of cerebrolysin in hypertensive supratentorial intracranial hemorrhages: results of a randomized triple blind placebo-controled study]. Zh Nevrol Psikhiatr Im S S Korsakova 2009, 109(1): 20-6.